HARROW INC (HROW) Stock News
NASDAQ:HROW - Nasdaq - US4158581094 - Common Stock - Currency: USD
HROW Latest News, Press Relases and Analysis
William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy
Harrow licensed U.S. rights to FDA-approved BYQLOVI for post-surgical eye pain and adds momentum to its branded ophthalmic drug strategy.
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
/PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW),...
Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout”
We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at where Harrow, Inc. (NASDAQ:HROW) stands against other stocks on Jim Cramer’s radar recently. On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor […]
Harrow to Present at Two Investor Conferences in May
Harrow Health Posts Larger Loss In Q1, But Retail Enthusiasm Grows As Dry Eye Disease Drug Drives Revenue
The company reported a net loss of $17.8 million, or 38 cents per share, compared to a loss of $13.6 million in the same period last year. Despite the wider loss, Harrow reiterated its 2025 revenue target of over $280 million.
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
Harrow (HROW) delivered earnings and revenue surprises of -2,000% and 19.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: SXTP
Harrow Announces First-Quarter 2025 Financial Results
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
Harrow (HROW) Q4 Earnings and Revenues Top Estimates
Harrow (HROW) delivered earnings and revenue surprises of 127.27% and 1.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ELV
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
Harrow Launches VEVYE® Access for All
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
